TGTX
TG THERAPEUTICS, INC.
Key Financials
Operating Income
$123.3M
↑ 194.1%
Revenue
$616.3M
↑ 87.3%
Net Income
$447.2M
↑ 1812.4%
EPS (Diluted)
$2.77
↑ 1746.7%
Shareholders' Equity
$648.0M
↑ 191.4%
Total Liabilities
$415.2M
↑ 16.9%
Total Assets
$1.1B
↑ 84.1%
Cash & Equivalents
$79.1M
↓ 56.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/7/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 8-K | 6/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TGTX |
| Company Name | TG THERAPEUTICS, INC. |
| CIK | 1001316 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (212) 554-4484 |